On May 20, 2024, Dr. Aditya Bardia and his colleagues published the final results of the Phase III ASCENT trial, reinforcing Sacituzumab Govitecan (SG) as a superior treatment option over chemotherapy for metastatic triple-negative breast cancer (mTNBC).
Key Findings:
Progression-free survival (PFS): 4.8 months with SG vs. 1.7 months with chemotherapy (HR: 0.41).
Overall survival (OS): 11.8 months with SG vs. 6.9 months with chemotherapy (HR: 0.51).
Trop-2 Expression: SG improved PFS across all Trop-2 expression quartiles, with a trend toward improved OS.
Safety: Manageable profile with ≤5% treatment-related discontinuations and no treatment-related deaths.
These results confirm the clinical benefit of Sacituzumab Govitecan over chemotherapy, reinforcing its role in mTNBC treatment.
Congratulations to Dr. Aditya Bardia and co-authors, including Hope Rugo, Sara Tolaney, Dr. Javier Cortés Castán, Martine Piccart-Gebhart, Sibylle Loibl, and Scott T. Hohfess.
Read the full study here: https://lnkd.in/eBt_RUtb
